Tricuspid Valve Intervention Guidelines

Classification and Diagnosis

The European Society of Cardiology recommends classification of tricuspid regurgitation into primary (organic) and secondary (functional) types, with primary TR resulting from structural abnormalities of the tricuspid valve apparatus, including leaflet damage, chordal rupture, vegetation, or congenital abnormalities 1, 2
Secondary TR results from tricuspid annular dilation and/or leaflet tethering without primary valve pathology, and is most commonly associated with right ventricular dilation and dysfunction 1, 2
Echocardiographic criteria for severe TR include a central jet ≥50% of the right atrium, dense continuous wave Doppler signal with triangular shape, vena contracta width ≥7 mm, PISA radius >9 mm, hepatic vein systolic flow reversal, EROA ≥0.4 cm², regurgitant volume ≥45 mL/beat, and dilated right heart chambers 1, 2

Indications for Intervention

The American College of Cardiology and American Heart Association recommend surgery for symptomatic patients with severe primary TR without severe right ventricular dysfunction (Class I, Level C) 1, 2
The European Society of Cardiology recommends surgery for symptomatic patients with severe primary TR without severe right ventricular dysfunction (Class I, Level C) 1, 2
TV surgery is strongly recommended for patients with severe TR undergoing left-sided valve surgery (Class I, Level B-NR - ACC/AHA; Class I, Level C - ESC) 1, 3, 2

Surgical Approach

The European Society of Cardiology recommends TV repair with a prosthetic ring as the first-line surgical approach when intervention is indicated 1, 3
TV repair is preferable to replacement when feasible due to better post-operative outcomes 1, 3

Medical Management

Guideline-directed medical therapy for heart failure with reduced ejection fraction is the first-line treatment in isolated primary and secondary TR 1, 4
Diuretics, particularly loop diuretics, are recommended for symptom relief in patients with right-sided heart failure and congestion 1, 4
Aldosterone antagonists may be beneficial in managing TR-related volume overload 4
Rhythm control strategies should be considered in patients with TR and atrial fibrillation 4

Follow-up and Monitoring

Regular echocardiographic assessment is essential to evaluate TR progression, right ventricular function, and response to therapy 4
Exercise stress echocardiography and cardiopulmonary exercise testing may be considered in asymptomatic patients to assess exercise capacity and risk stratification 2, 4

Management of Tricuspid Regurgitation

Diagnostic Approach and Management

Functional tricuspid regurgitation is most often caused by right ventricular pressure and/or volume overload, commonly due to left-sided heart disease, pulmonary hypertension, or right ventricular intrinsic disease, as noted by the European Society of Cardiology 5
Transthoracic echocardiography is the first-line imaging modality for assessing tricuspid regurgitation severity and right ventricular size and function, according to the European Heart Journal 6
Additional imaging with 3D echocardiography, cardiovascular magnetic resonance, or right heart catheterization may be considered when clinical and non-invasive data are discordant, as recommended by the European Heart Journal 6, 7
The European Society of Cardiology recommends regular monitoring for development of pulmonary hypertension in patients with tricuspid regurgitation 5
Prophylactic tricuspid valve repair may be considered during left-sided heart surgery if tricuspid annular dilation is present, with a Class IIa recommendation by European guidelines and Class IIb by American and Japanese guidelines 6, 7
The American College of Cardiology and other guidelines suggest that early intervention for tricuspid regurgitation during left-sided valve surgery may prevent subsequent progression of tricuspid regurgitation and right ventricular dysfunction, although the specific recommendation is not provided in the article, the concept is supported by 5, 6, 7

Management of Mild-Moderate Tricuspid Regurgitation with Grade II Diastolic Dysfunction

Clinical Context and Risk Stratification

The American College of Cardiology recommends that patients with mild-to-moderate tricuspid regurgitation without severe TR criteria, normal right ventricular function, and no pulmonary hypertension be monitored closely, as this clinical picture does not meet criteria for surgical intervention 8, 9, 10
Normal right ventricular function is defined by a TAPSE of 2.3 cm and S' velocity of 12 cm/s, and no pulmonary hypertension is indicated by a PASP of 23 mmHg, which is normal 8
The absence of severe TR, normal RV function, and no signs of right heart failure are favorable prognostic indicators that suggest the TR is not hemodynamically significant 8, 9

Medical Management Strategy

Critical Monitoring Parameters

The American College of Cardiology suggests monitoring tricuspid annular diameter, with progression to ≥40 mm (or ≥21 mm/m²) triggering consideration for intervention if left-sided surgery becomes necessary 8, 11, 12
Right ventricular size and function should be monitored, with deterioration in TAPSE (<17 mm) or S' velocity (<10 cm/s) indicating worsening RV function 8
Pulmonary artery pressure should be monitored, with development of pulmonary hypertension (PASP >35-40 mmHg) changing management 8, 9
Progression of TR severity should be monitored, with advancement to severe TR (vena contracta ≥7 mm, EROA ≥0.4 cm², central jet ≥50% RA) indicating a need for intervention 10, 13

Key Prognostic Considerations

When Surgical Intervention Would Be Indicated

Surgical intervention would become appropriate if TR progresses to severe with symptoms of right heart failure unresponsive to medical therapy, or if progressive RV dilation or systolic dysfunction develops despite medical management 8, 9, 10, 11, 12
The American College of Cardiology recommends concomitant tricuspid valve repair when a patient requires left-sided valve surgery and has tricuspid annular dilation ≥40 mm or ≥21 mm/m² (Class IIa) 8, 11, 12
Tricuspid valve repair with a prosthetic ring is the preferred surgical approach when intervention becomes necessary, as it provides superior outcomes compared to replacement 10

Management of Tricuspid Regurgitation

Medical Management Strategy

The European Heart Journal recommends initiating guideline-directed medical therapy for heart failure with reduced ejection fraction as first-line treatment for both primary and secondary isolated TR, and medical therapy should not delay surgical or transcatheter referral when intervention is already indicated 14
Rhythm control strategies in patients with concurrent atrial fibrillation are recommended, as AF-induced annular remodeling is a major determinant of secondary TR 14

Surgical Intervention Indications

The European Heart Journal suggests operating on symptomatic patients with severe primary TR without severe RV dysfunction, and do not operate if severe irreversible RV dysfunction or irreversible pulmonary hypertension is present, as surgery is likely futile 14
TV surgery for patients with severe TR undergoing left-sided valve surgery is recommended, regardless of symptoms when severe TR is present, with a Class I, Level B-NR (ACC/AHA) and Class I, Level C (ESC) recommendation 14

Surgical Technique Selection

The European Heart Journal recommends using rigid or semi-rigid ring annuloplasty as the gold standard surgical technique, as they are superior to flexible annuloplasty bands in preventing late recurrent TR 14
Valve replacement instead of repair is considered in patients with severe RV dysfunction, very large annuli, or significant leaflet tenting 14

Monitoring and Follow-Up Parameters

The European Heart Journal endorses using RV free wall longitudinal strain from 2D speckle-tracking echocardiography for more sensitive RV function assessment 14
Exercise stress echocardiography and cardiopulmonary exercise testing in asymptomatic patients are considered for risk stratification and exercise capacity assessment 14

Transcatheter Tricuspid Valve Intervention (TTVI)

Referral to tertiary heart valve centers with TTVI expertise is recommended for high-risk surgical patients with severe TR 14

Critical Pitfalls to Avoid

The European Heart Journal recommends not performing TV surgery in patients with tricuspid annular dilation but absent or only trace TR 14
Flexible bands should not be used when rigid/semi-rigid rings are available, as they have higher rates of recurrent TR 14

Management of Severe Tricuspid Regurgitation

Medical Management Strategy

The American Heart Association recommends loop diuretics as the cornerstone for relieving systemic and hepatic congestion in patients with severe tricuspid regurgitation, with aggressive titration to relieve symptoms 15
Valve replacement instead of repair should be considered in specific circumstances, such as severe right ventricular dysfunction, very large annuli, significant leaflet tenting, or valve destruction, according to the American College of Cardiology 15

Surgical Intervention Indications

The American College of Cardiology recommends operating on patients with severe tricuspid regurgitation undergoing left-sided valve surgery, regardless of symptoms, as concomitant repair prevents subsequent tricuspid regurgitation progression 15
Operate on patients with isolated, symptomatic severe tricuspid stenosis, as recommended by the American Heart Association 15

Management of Severe Tricuspid Regurgitation

Initial Medical Therapy

The European Heart Journal recommends serial transthoracic echocardiography to monitor TR severity, RV size and function, and pulmonary pressures, with particular attention to tricuspid annular dilation progression (threshold ≥40 mm or ≥21 mm/m²) 16

Critical Assessment for Intervention Candidacy

The European Heart Journal suggests that irreversible liver dysfunction from chronic hepatic congestion is a contraindication to intervention 16

Monitoring Parameters During Medical Management

According to the European Heart Journal, serial transthoracic echocardiography is essential to monitor TR severity, RV size and function, and pulmonary pressures, with RV free wall longitudinal strain from 2D speckle-tracking echocardiography providing a more sensitive assessment of RV function than TAPSE alone 16

Initial Management of Right-Sided Pleural Effusion in Severe Tricuspid Regurgitation

Medical Management Strategy

The American College of Cardiology recommends aggressive diuretic therapy to relieve right-sided heart failure symptoms, while simultaneously evaluating the pleural effusion to exclude other etiologies and optimizing medical therapy for the underlying severe tricuspid regurgitation 17
Loop diuretics are the cornerstone of initial management for symptomatic relief of right-sided heart failure and pleural effusion, with aggressive titration of furosemide (or equivalent loop diuretic) necessary to relieve systemic and hepatic congestion 17
Aldosterone antagonists provide additive benefit, particularly when hepatic congestion is present, as this promotes secondary hyperaldosteronism 17

Critical Assessment for Surgical Intervention

Surgery is recommended (Class I) for symptomatic patients with severe primary TR without severe RV dysfunction or irreversible pulmonary hypertension, according to the American College of Cardiology 17, 18
If the patient requires left-sided valve surgery for any reason, concomitant tricuspid valve repair is strongly recommended (Class I, Level B-NR) regardless of symptoms when severe TR is present, as stated by the American College of Cardiology 17, 18

Common Pitfalls to Avoid

Delaying surgical evaluation in symptomatic patients with severe TR and preserved RV function can lead to progressive RV dysfunction and worsen surgical outcomes, as warned by the American College of Cardiology 17
Reoperation for isolated TR after previous left-sided valve surgery carries 10-25% perioperative mortality, emphasizing the importance of addressing severe TR at the time of initial left-sided valve surgery, according to the American College of Cardiology 17

Management of Tricuspid Regurgitation

Diagnosis and Monitoring

The European Society of Cardiology recommends monitoring progression of TR severity, defined by vena contracta ≥7 mm, EROA ≥0.4 cm², or central jet ≥50% of right atrium, to guide management decisions 19
The American Heart Association suggests monitoring left ventricular dimensions, with progression of LV dilation defined as end-diastolic dimension approaching 75 mm or end-systolic dimension approaching 55 mm, to assess disease severity 20
Monitoring of tricuspid annular diameter is crucial, with progression to ≥40 mm (or ≥21 mm/m² indexed) being a key threshold that triggers consideration for concomitant tricuspid repair if left-sided valve surgery becomes necessary 19
Right ventricular function assessment using TAPSE (threshold <17 mm) and S' velocity (threshold <10 cm/s) is essential to detect early RV dysfunction 20

Surgical Intervention

The European Heart Association recommends concomitant tricuspid valve repair when left-sided valve surgery is necessary and tricuspid annular dilation is ≥40 mm or ≥21 mm/m², with a Class IIa recommendation 19
Surgical intervention is indicated when TR progresses to severe with symptoms of right heart failure unresponsive to medical therapy, with a Class I indication 19

Prognosis

The natural history of mild functional TR involves early atrial enlargement and tricuspid annular dilation, followed by late right ventricular dilation when TR becomes severe 20

Guideline Recommendations for Tricuspid Regurgitation Management

Surgical Indications (Class I – Strong Recommendation)

Surgery is indicated for symptomatic patients with severe primary tricuspid regurgitation who do not have severe, irreversible right‑ventricular dysfunction. – European Society of Cardiology (ESC) guideline 2017. 21
Surgery is indicated for any patient with severe tricuspid regurgitation (primary or secondary) who is already undergoing left‑sided valve surgery. – ESC guideline 2017. 22

Concomitant Repair Considerations (Class IIa – Moderate Recommendation)

Concomitant tricuspid valve repair should be considered in patients undergoing left‑sided valve surgery when mild‑to‑moderate tricuspid regurgitation is present and the annular diameter is ≥ 40 mm (or ≥ 21 mm/m² indexed). – American College of Cardiology (ACC) guideline 2023. 23
Surgery (repair or replacement) should be considered in asymptomatic or mildly symptomatic patients with isolated severe primary tricuspid regurgitation who demonstrate progressive right‑ventricular dilation or worsening right‑ventricular function. – ESC guideline 2017. 22

Preferred Surgical Technique (Class IIa – Moderate Recommendation)

Rigid or semi‑rigid annuloplasty rings are the gold‑standard for treating secondary tricuspid regurgitation, providing superior late‑recurrence prevention compared with flexible bands. – ESC guideline 2017. 22
When feasible, tricuspid valve repair is preferred over valve replacement because it yields better postoperative outcomes. – ESC guideline 2017. 22
Valve replacement is advised when leaflets are markedly tethered and the annulus is severely dilated, or when there is severe right‑ventricular dysfunction, a very large annulus, or extensive valve destruction. – ESC guideline 2017. 22

Transcatheter Therapy Position (Class IIb – Weak Recommendation)

Percutaneous tricuspid repair techniques are still in an early developmental stage; further robust evaluation is required before definitive guideline recommendations can be made. – ESC guideline 2017. 22

Anatomical Thresholds Triggering Intervention (Class IIa – Moderate Recommendation)

A tricuspid annular diameter ≥ 40 mm (or ≥ 21 mm/m² indexed) serves as a specific echocardiographic trigger to consider concomitant tricuspid repair during left‑sided valve surgery. – ACC guideline 2023. 23

All facts are derived from cited guideline statements (ESC or ACC) and include the strength of recommendation where provided.

Guideline Recommendations for Management of Severe Tricuspid Regurgitation

Initial Medical Management

Optimize treatment of conditions that raise left‑sided filling pressures (e.g., systemic hypertension) to reduce secondary tricuspid regurgitation burden. ACC/AHA guideline 24

Surgical Indications

Class I (Strong Recommendation)

Perform concomitant tricuspid surgery in any patient with severe tricuspid regurgitation (primary or secondary) undergoing left‑sided valve surgery, regardless of symptoms, to prevent progression and avoid the 10–25 % peri‑operative mortality associated with isolated re‑operation. ACC/AHA & ESC guidelines 24, 25
Operate promptly in symptomatic patients with severe primary tricuspid regurgitation who have preserved right‑ventricular function and no irreversible pulmonary hypertension; delaying surgery leads to irreversible RV damage, organ failure, and poor late outcomes. ACC/AHA & ESC guidelines 24, 25

Class IIa (Should Be Considered)

Address moderate primary tricuspid regurgitation when left‑sided valve surgery is performed. ESC guideline 25
Repair mild‑to‑moderate secondary tricuspid regurgitation when the tricuspid annular diameter is ≥40 mm (or ≥21 mm/m² indexed) during left‑sided valve surgery; about 25 % of uncorrected moderate TR progresses post‑operatively. ACC/AHA & ESC guidelines 24, 25
Operate on asymptomatic or minimally symptomatic severe primary tricuspid regurgitation if there is progressive RV dilation or deteriorating RV function, to prevent irreversible RV dysfunction. ACC/AHA & ESC guidelines 24, 25
Consider surgery for persistent severe tricuspid regurgitation after prior left‑sided valve surgery in symptomatic patients with progressive RV dilation/dysfunction, provided there is no left‑sided valve disease, severe biventricular dysfunction, or severe pulmonary vascular disease. ESC guideline 25

Surgical Technique Selection

Prefer tricuspid valve repair using a rigid or semi‑rigid annuloplasty ring; repair yields superior postoperative outcomes compared with replacement. ACC/AHA guideline 24
Choose valve replacement instead of repair when severe RV dysfunction, markedly dilated annulus, significant leaflet tethering, or extensive valve destruction (e.g., carcinoid, radiation, endocarditis) is present. ACC/AHA guideline 24
When replacement is required, select mechanical versus bioprosthetic valve based on individual thrombotic/anticoagulation risk versus durability; meta‑analyses show no difference in survival between valve types. ACC/AHA guideline 24

Absolute Contraindications to Intervention

Do not operate or perform transcatheter tricuspid valve intervention in patients with severe irreversible right‑ventricular dysfunction, as surgery is futile and outcomes are poor. ESC guideline 25
Do not intervene when irreversible pulmonary hypertension is present, because peri‑operative mortality is prohibitively high. ACC/AHA guideline 24

Monitoring During Medical Management

Perform serial transthoracic echocardiography; an increase in tricuspid annular diameter to ≥40 mm (or ≥21 mm/m² indexed) should trigger consideration of intervention if left‑sided valve surgery becomes necessary. ACC/AHA guideline 24

Critical Pitfalls to Avoid

Never postpone addressing severe tricuspid regurgitation at the time of left‑sided valve surgery; isolated re‑operation carries a 10–25 % mortality versus minimal added risk when performed concomitantly. ACC/AHA guideline 24
Recognize that functional tricuspid regurgitation does not reliably resolve after treating left‑sided disease alone; the traditional teaching is incorrect. ACC/AHA guideline 24